162 related articles for article (PubMed ID: 34107813)
1. Rhabdomyosarcoma: How Advanced Molecular Methods Are Shaping the Diagnostic and Therapeutic Paradigm.
Giannikopoulos P; Parham DM
Pediatr Dev Pathol; 2021; 24(5):395-404. PubMed ID: 34107813
[TBL] [Abstract][Full Text] [Related]
2. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee.
Butel T; Karanian M; Pierron G; Orbach D; Ranchere D; Cozic N; Galmiche L; Coulomb A; Corradini N; Lacour B; Proust S; Guerin F; Boutroux H; Rome A; Mansuy L; Vérité C; Defachelles AS; Tirode F; Minard-Colin V
Cancer Med; 2020 Apr; 9(8):2698-2709. PubMed ID: 32087612
[TBL] [Abstract][Full Text] [Related]
3. Histology and fusion status in rhabdomyosarcoma.
Rudzinski ER
Am Soc Clin Oncol Educ Book; 2013; ():425-8. PubMed ID: 23714565
[TBL] [Abstract][Full Text] [Related]
4. FGFR1 fusions as a novel molecular driver in rhabdomyosarcoma.
de Traux De Wardin H; Cyrta J; Dermawan JK; Guillemot D; Orbach D; Aerts I; Pierron G; Antonescu CR
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23232. PubMed ID: 38607246
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of pleomorphic rhabdomyosarcoma reveals a genomic signature distinct from that of embryonal rhabdomyosarcoma.
Saoud C; Dermawan JK; Sharma AE; Tap W; Wexler LH; Antonescu CR
Genes Chromosomes Cancer; 2024 May; 63(5):e23238. PubMed ID: 38722224
[TBL] [Abstract][Full Text] [Related]
6. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
[TBL] [Abstract][Full Text] [Related]
7. Molecular diagnostics in the management of rhabdomyosarcoma.
Arnold MA; Barr FG
Expert Rev Mol Diagn; 2017 Feb; 17(2):189-194. PubMed ID: 28058850
[TBL] [Abstract][Full Text] [Related]
8. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
[TBL] [Abstract][Full Text] [Related]
9. SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma.
Karanian M; Pissaloux D; Gomez-Brouchet A; Chevenet C; Le Loarer F; Fernandez C; Minard V; Corradini N; Castex MP; Duc-Gallet A; Blay JY; Tirode F
Am J Surg Pathol; 2020 May; 44(5):607-616. PubMed ID: 32187044
[TBL] [Abstract][Full Text] [Related]
10. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
[TBL] [Abstract][Full Text] [Related]
11. NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma.
Tombolan L; Poli E; Martini P; Zin A; Romualdi C; Bisogno G; Lanfranchi G
Oncotarget; 2017 May; 8(20):33086-33099. PubMed ID: 28380437
[TBL] [Abstract][Full Text] [Related]
12. Methylation profiling reveals novel molecular classes of rhabdomyosarcoma.
Clay MR; Patel A; Tran Q; Hedges DJ; Chang TC; Stewart E; Charville G; Cline C; Dyer MA; Orr BA
Sci Rep; 2021 Nov; 11(1):22213. PubMed ID: 34782706
[TBL] [Abstract][Full Text] [Related]
13. Rhabdomyosarcoma: Updates on classification and the necessity of molecular testing beyond immunohistochemistry.
Dehner CA; Rudzinski ER; Davis JL
Hum Pathol; 2024 May; 147():72-81. PubMed ID: 38135061
[TBL] [Abstract][Full Text] [Related]
14. Epithelioid rhabdomyosarcoma: a clinicopathologic and molecular study.
Zin A; Bertorelle R; Dall'Igna P; Manzitti C; Gambini C; Bisogno G; Rosolen A; Alaggio R
Am J Surg Pathol; 2014 Feb; 38(2):273-8. PubMed ID: 24418861
[TBL] [Abstract][Full Text] [Related]
15. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
[TBL] [Abstract][Full Text] [Related]
16. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
Shern JF; Selfe J; Izquierdo E; Patidar R; Chou HC; Song YK; Yohe ME; Sindiri S; Wei J; Wen X; Rudzinski ER; Barkauskas DA; Lo T; Hall D; Linardic CM; Hughes D; Jamal S; Jenney M; Chisholm J; Brown R; Jones K; Hicks B; Angelini P; George S; Chesler L; Hubank M; Kelsey A; Gatz SA; Skapek SX; Hawkins DS; Shipley JM; Khan J
J Clin Oncol; 2021 Sep; 39(26):2859-2871. PubMed ID: 34166060
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group.
Davicioni E; Anderson MJ; Finckenstein FG; Lynch JC; Qualman SJ; Shimada H; Schofield DE; Buckley JD; Meyer WH; Sorensen PH; Triche TJ
Am J Pathol; 2009 Feb; 174(2):550-64. PubMed ID: 19147825
[TBL] [Abstract][Full Text] [Related]
18. Zebrafish Rhabdomyosarcoma.
Phelps M; Chen E
Adv Exp Med Biol; 2016; 916():371-89. PubMed ID: 27165362
[TBL] [Abstract][Full Text] [Related]
19. What is new in the biology and treatment of pediatric rhabdomyosarcoma?
Hawkins DS; Gupta AA; Rudzinski ER
Curr Opin Pediatr; 2014 Feb; 26(1):50-6. PubMed ID: 24326270
[TBL] [Abstract][Full Text] [Related]
20. Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma.
Casey DL; Wexler LH; Pitter KL; Samstein RM; Slotkin EK; Wolden SL
Clin Cancer Res; 2020 Mar; 26(5):1135-1140. PubMed ID: 31699828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
